FDA clears pTau217 blood test for Alzheimer's disease - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA clears pTau217 blood test for Alzheimer's disease

The assay uses the same validated clinical cutoffs across primary and specialty care settings.

  • By

  • Kathryn Wighton

  • August 24, 2026

  • 2 min

Share

Clinical Scorecard: FDA clears pTau217 blood test for Alzheimer's disease

At a Glance

CategoryDetail
ConditionAlzheimer's disease
Key MechanismsIdentifies amyloid pathology using pTau217 biomarker
Target PopulationPatients aged 55 years and older with cognitive decline
Care SettingClinical laboratories

Key Highlights

  • FDA cleared Elecsys pTau217 Plasma blood test for Alzheimer's disease
  • Test aids in identifying amyloid pathology
  • Returns classifications: positive, intermediate, or negative
  • Highly concordant with amyloid PET imaging
  • Designed for use on Roche cobas laboratory instruments

Guideline-Based Recommendations

Diagnosis

  • Use test results alongside clinical information and other findings

Management

  • Consider further testing (e.g., PET imaging, CSF testing) based on results

Monitoring & Follow-up

  • Not established for predicting future dementia or tracking therapeutic responses

Risks

  • Test results should not be used in isolation for diagnosis

Patient & Prescribing Data

Patients aged 55 years and older with cognitive decline

May help identify patients for further evaluation

Clinical Best Practices

  • Incorporate test into existing laboratory workflows
  • Use in conjunction with other diagnostic evaluations

Related Resources & Content

Original Source(s)

FDA clears pTau217 blood test for Alzheimer's disease

  • by Kathryn Wighton

  • August 24, 2026

Related Content

Metabolic Health Tied to Dementia

In two population-based cohorts, metabolically unhealthy status generally showed higher dementia risk estimates, while metabolically healthy obesity was not associated with increased risk in primary analyses.

FDA Monthly Preview: Key August Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Low Follow-Up After Behavioral ED Care

Follow-up occurred after fewer than 15% of mental health ED visits and about 11% of substance use–related visits in Washington Medicaid claims.